Order Article Reprints

Moiseenko F, Radulovic M, Tsvetkova N, Chernobrivceva V, Gabina A, Oganesian A, Makarkina M, Elsakova E, Krasavina M, Barsova D, et al. Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations. Cancers. 2025; 17(11):1790. https://doi.org/10.3390/cancers17111790

Moiseenko, Fedor, Marko Radulovic, Nadezhda Tsvetkova, Vera Chernobrivceva, Albina Gabina, Any Oganesian, Maria Makarkina, Ekaterina Elsakova, Maria Krasavina, Daria Barsova, and et al. 2025. "Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations" Cancers 17, no. 11: 1790. https://doi.org/10.3390/cancers17111790

Moiseenko, F., Radulovic, M., Tsvetkova, N., Chernobrivceva, V., Gabina, A., Oganesian, A., Makarkina, M., Elsakova, E., Krasavina, M., Barsova, D., Artemeva, E., Khenshtein, V., Levchenko, N., Chubenko, V., Egorenkov, V., Volkov, N., Bogdanov, A., & Moiseyenko, V. (2025). Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations. Cancers, 17(11), 1790. https://doi.org/10.3390/cancers17111790